December 19, 2013

Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program

Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment

 

Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor Clinical Program
Collaboration represents the first time the ACC’s PINNACLE Registry Research Alliance will be used for clinical trial recruitment

Paris, France and Tarrytown, New York – December 19, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ : REGN) announced today an innovative collaboration with the American College of Cardiology (ACC) focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low- density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.